Patents by Inventor Patrick René Angibaud

Patrick René Angibaud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer
    Publication number: 20230203011
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 19, 2022
    Publication date: June 29, 2023
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20230039917
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: May 2, 2022
    Publication date: February 9, 2023
    Inventors: Xuedong DAI, Olivier Alexis Georges QUEROLLE, Daniel Jason KROSKY, Wei CAI, Liqiang FU, Linglong KONG, Yingtao LIU, Zhao-Kui WAN, Barbara MORSCHHÄUSER GEB. HERKERT, Vineet PANDE, James Patrick EDWARDS, Aaron Nathaniel PATRICK, Patrick René ANGIBAUD, Virginie Sophie PONCELET
  • Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
    Patent number: 11542247
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 3, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • Azepane inhibitors of menin-MLL interaction
    Patent number: 11530226
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: December 20, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • Exo-aza spiro inhibitors of menin-MLL interaction
    Patent number: 11396517
    Abstract: Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 26, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuedong Dai, Olivier Alexis Georges Querolle, Daniel Jason Krosky, Wei Cai, Liqiang Fu, Linglong Kong, Yingtao Liu, Zhao-Kui Wan, Barbara Morschhäuser Geb. Herkert, Vineet Pande, James Patrick Edwards, Aaron Nathaniel Patrick, Patrick René Angibaud, Virginie Sophie Poncelet
  • Spiro Bicyclic Inhibitors Of Menin-MLL Interaction
    Publication number: 20220227786
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: November 29, 2021
    Publication date: July 21, 2022
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • PYRAZOLYL QUINOXALINE KINASE INHIBITORS
    Publication number: 20220135544
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity
    Patent number: 11267804
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 8, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV
    Publication number: 20220033396
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial vims (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment or prevention of respiratory syncytial vims infection.
    Type: Application
    Filed: November 25, 2019
    Publication date: February 3, 2022
    Inventors: Jérome Émile Georges GUILLEMONT, David Francis Alain LANÇOIS, Sovy CHAO, Patrick René ANGIBAUD, Guillaume Jean Maurice MERCEY, Pierre Jean-Marie Bernard RABOISSON, Antoine Benjamin MICHAUT, Peter RIGAUX
  • Spiro bicyclic inhibitors of menin-MLL interaction
    Patent number: 11220517
    Abstract: The present invention relates to compounds of formula (I): wherein the variables have the meaning defined in the Specification. The compounds according to the present invention are useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: January 11, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • Compounds
    Patent number: 11155555
    Abstract: The invention relates to new quinoxaline, quinoline and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: October 26, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Helene France Solange Colombel, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
    Patent number: 11130751
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: September 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry François Alain Jean Jousseaume
  • Fused bicyclic inhibitors of menin-MLL interaction
    Patent number: 10975100
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick
  • Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors
    Patent number: 10894793
    Abstract: The present invention relates to bicyclic pyridine, pyrazine, and pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 19, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Didier Jean-Claude Berthelot, Laurence Anne Mevellec, Patrick Rene Angibaud, Sophie Coupa, Christophe Gabriel Marcel Demestre, Lieven Meerpoel, Guillaume Jean Maurice Mercey, Christophe Meyer, Elisabeth Therese Jeanne Pasquter, Isabelle Noelle Constance Pilatte, Virginie Sophie Poncelet, Olivier Alexis Georges Querolle
  • Azepane Inhibitors Of Menin-MLL Interaction
    Publication number: 20200339594
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 29, 2020
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • Azepane inhibitors of menin-MLL interaction
    Patent number: 10745409
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 18, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noëlle Constance Pilatte
  • NEW COMPOUNDS
    Publication number: 20200255430
    Abstract: The invention relates to new quinoxaline, quinoline and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: September 22, 2016
    Publication date: August 13, 2020
    Inventors: Patrick Rene ANGIBAUD, Diego Fernando Domenico BROGGiN!, Helene France Soiange COLOMBEL, Filip Albert C CUYCKENS, Steven Anna HOSTYN, Rusell Mark JONES, Olivier Alexis Georges QUEROLLE, Wim VERMEULEN
  • NEW COMPOUNDS
    Publication number: 20200255401
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: September 22, 2016
    Publication date: August 13, 2020
    Inventors: Patrick Rene ANGIBAUD, Diego Fernando Domenico BROGGINI, Filip Albert C CUYCKENS, Steven Anna HOSTYN, Russell Mark JONES, Olivier Alexis Georges QUEROLLE, Wim VERMEULEN
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS
    Publication number: 20200181132
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: March 29, 2018
    Publication date: June 11, 2020
    Inventors: Patrick Rene Angibaud, Olivier, Alexis Georges QUEROLLE, Didier Jean-Claude BERTHELOT, Christophe MEYER, Matthieu Philippe, Victor WILLOT, Lieven MEERPOEL, Thierry, François Alain, Jean JOUSSEAUME
  • FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20200172556
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 4, 2020
    Inventors: Patrick Rene ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK